08 / Industry · Analysis
Remedy Robotics raises funds for vascular robot
The funding supports clinical trial and commercialisation preparations as Remedy Robotics develops technology combining remote procedures with autonomous surgery.
Remedy Robotics, a US medical robotics company, raised about 83 billion won to develop a vascular intervention robot, AI Times reported.
The report identified the company's product as the N1 System, an AI-based robotic platform for vascular interventions, procedures performed inside blood vessels. Its development combines remote procedures with autonomous surgery.
AI Times presented the investment against a wider shift in medical AI from image analysis and diagnostic assistance towards manipulating instruments during procedures. That framing puts the focus on what the funding supports: development and preparations for clinical trials and commercialisation.
Funding for clinical trial preparations
AI Times described the financing as a Series B round. According to the report, Remedy Robotics secured the funds to prepare for clinical trials and commercialisation.
The reported purpose places the investment at a stage of product development and preparation. Raising capital supports that work, but does not itself establish clinical results.
Combining remote procedures with autonomous surgery
According to AI Times, Remedy Robotics is developing technology that combines remote procedures with autonomous surgery. The robot under development manipulates procedural instruments inside blood vessels.
The report's account therefore centres on a development programme whose next steps involve clinical trial and commercialisation preparations. The investment provides funding for those steps; clinical performance remains a separate question from the financing.